
|Videos|June 5, 2017
An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer
Author(s)Kathleen N. Moore, MD
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.
Advertisement
Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
2
FDA Grants Breakthrough Therapy Designation to Sofi-Cel for R/R T-ALL/LBL
3
Exploring Radiation Therapy’s Reach in Prostate Cancer
4
BNT113 Garners Fast-Track Designation in PD-L1+ HPV16+ HNSCC
5














































